Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Bortezomib is a proteasome inhibitor with remarkable preclinical and clinical antitumor activity in multiple myeloma (MM) patients. The initial rationale for its use in MM was inhibition of nuclear factor (NF)-κB activity by blocking proteasomal degradation of inhibitor of κBα (IκBα). Bortezomib inh...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hideshima, Teru, Ikeda, Hiroshi, Chauhan, Dharminder, Okawa, Yutaka, Raje, Noopur, Podar, Klaus, Mitsiades, Constantine, Munshi, Nikhil C., Richardson, Paul G., Carrasco, Ruben D., Anderson, Kenneth C.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2009
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2721785/
https://ncbi.nlm.nih.gov/pubmed/19436050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-01-199604
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares